This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Long-Term Combination Therapy Versus Monotherapy With Lithium and Carbamazepine in 46 Bipolar I Patients

Christopher Baethge, MD; Ross J. Baldessarini, MD; Kirsten Mathiske-Schmidt, PhD; John Hennen, MD; Anne Berghöfer, MD; Bruno Müller-Oerlinghausen, MD; Tom Bschor, MD; Mazda Adli, MD; and Michael Bauer, MD, PhD

Published: February 15, 2005

Article Abstract

Background: Despite wide clinical use of mood-stabilizer combinations for long-term treatment of patients with bipolar disorder, research on risks and benefits of this practice is limited. We found 14 small, usually brief, clinical trials of maintenance treatment with lithium plus carbamazepine. These trials suggest added benefit of combination treatment over use of either agent alone but also indicate the need for further studies.

Method: In a post hoc analysis, we reviewed the course of 46 patients with DSM-IV-diagnosed bipolar I disorder identified as not improving during long-term monotherapy in a mood disorders clinic, comparing days per year hospitalized in 3 consecutive time periods: before prophylactic treatment, during monotherapy with lithium (N = 31) or carbamazepine (N = 15), and during their combined use (N = 46). Secondary outcome measures were rates of hospitalization, time to first recurrence of an affective episode, use of adjunctive treatments, and adverse effects. We compared outcomes with nonparametric bivariate methods and tested predictive factors by multiple regression.

Results: Subjects showed significant reductions in hospitalized days per year during combination therapy, averaging a decrease of 55.9% (p = .004). Among secondary outcomes, hospitalizations per year fell by 36.1%, and median time to recurrence nearly doubled during combination therapy. Rates of adverse effects increased 2.5-fold, compared with monotherapy, and use of adjunctive psychotropic agents increased by 21.9%.

Conclusion: Combining lithium with carbamazepine yielded substantial benefit but more adverse effects.

Volume: 66

Quick Links: Bipolar Disorder

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Skeletal and Dental Fractures Associated With Electroconvulsive Therapy

Recent data suggest the risk of skeletal or dental fracture with ECT may be as low as...